Cargando…
Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087986/ https://www.ncbi.nlm.nih.gov/pubmed/37057113 http://dx.doi.org/10.21037/tlcr-22-897 |
| _version_ | 1785022473745465344 |
|---|---|
| author | Lee, Kuan-Yu Hsu, Chen-Xiong |
| author_facet | Lee, Kuan-Yu Hsu, Chen-Xiong |
| author_sort | Lee, Kuan-Yu |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10087986 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100879862023-04-12 Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone? Lee, Kuan-Yu Hsu, Chen-Xiong Transl Lung Cancer Res Letter to the Editor AME Publishing Company 2023-03-01 2023-03-31 /pmc/articles/PMC10087986/ /pubmed/37057113 http://dx.doi.org/10.21037/tlcr-22-897 Text en 2023 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Letter to the Editor Lee, Kuan-Yu Hsu, Chen-Xiong Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone? |
| title | Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone? |
| title_full | Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone? |
| title_fullStr | Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone? |
| title_full_unstemmed | Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone? |
| title_short | Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone? |
| title_sort | adjuvant chemotherapy or immunotherapy for completely resected stage ib non-small cell lung cancer: still a grey zone? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087986/ https://www.ncbi.nlm.nih.gov/pubmed/37057113 http://dx.doi.org/10.21037/tlcr-22-897 |
| work_keys_str_mv | AT leekuanyu adjuvantchemotherapyorimmunotherapyforcompletelyresectedstageibnonsmallcelllungcancerstillagreyzone AT hsuchenxiong adjuvantchemotherapyorimmunotherapyforcompletelyresectedstageibnonsmallcelllungcancerstillagreyzone |